HC Wainwright Boosts Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Disc Medicine in a report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($6.19) per share for the year, up from their prior forecast of ($6.64). HC Wainwright has a “Buy” rating and a $127.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.54) per share. HC Wainwright also issued estimates for Disc Medicine’s Q4 2026 earnings at ($1.47) EPS, Q2 2027 earnings at ($1.87) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($0.86) EPS, FY2027 earnings at ($5.56) EPS, FY2028 earnings at ($4.01) EPS, FY2029 earnings at $0.78 EPS and FY2030 earnings at $6.23 EPS.

A number of other research analysts also recently issued reports on IRON. Guggenheim started coverage on shares of Disc Medicine in a research report on Monday. They set a “buy” rating and a $132.00 target price for the company. Morgan Stanley upped their price target on shares of Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. Cantor Fitzgerald increased their price target on Disc Medicine from $125.00 to $170.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. Truist Financial lifted their price objective on Disc Medicine from $83.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Finally, BMO Capital Markets lifted their price objective on Disc Medicine from $100.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.18.

Disc Medicine Stock Up 3.0%

NASDAQ:IRON opened at $81.26 on Tuesday. The firm has a market capitalization of $3.12 billion, a P/E ratio of -12.82 and a beta of 0.96. Disc Medicine has a 1-year low of $40.00 and a 1-year high of $99.50. The company’s fifty day moving average price is $71.23 and its 200-day moving average price is $70.97. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.10.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds have recently bought and sold shares of IRON. BlackRock Inc. acquired a new stake in Disc Medicine in the second quarter valued at approximately $180,502,000. Wellington Management Group LLP increased its position in shares of Disc Medicine by 0.3% in the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after buying an additional 5,975 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Disc Medicine by 191.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after buying an additional 735,300 shares during the period. Opaleye Management Inc. raised its stake in shares of Disc Medicine by 103.1% during the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after buying an additional 434,000 shares during the period. Finally, Aberdeen Group plc raised its stake in shares of Disc Medicine by 36.4% during the 3rd quarter. Aberdeen Group plc now owns 597,841 shares of the company’s stock worth $39,135,000 after buying an additional 159,667 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Transactions at Disc Medicine

In other news, CEO John Quisel sold 33,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the sale, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $17,892,965.60. This represents a 12.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the sale, the chief operating officer owned 54,324 shares in the company, valued at $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 168,046 shares of company stock valued at $13,191,034 in the last ninety days. 3.76% of the stock is currently owned by corporate insiders.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for FY2026, FY2027, and FY2028 to losses of $6.19, $5.56, and $4.01 per share, respectively, versus prior estimates of $6.64, $6.47, and $4.62. It also improved its Q4 2026 estimate to a $1.47 loss from a $1.74 loss. The analyst reaffirmed a Buy rating and $127 target, a constructive signal for shares. Disc Medicine analyst estimate updates
• Positive Sentiment: A separate report cited a $124.18 consensus price target, suggesting analysts see potential upside relative to the stock’s recent trading level. Disc Medicine consensus target price
• Negative Sentiment: HC Wainwright lowered its projected earnings for FY2029 to $0.78 per share from $1.03, and FY2030 to $6.23 from $7.34. These cuts temper the positive near-term revisions, though the forecasts still project a shift to profitability in 2029.

Disc Medicine Company Profile

Disc Medicine, Inc is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function.

The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.